Latest News 2012

May 21, 2013
uniQure and consortium to receive EUR 2.5 million Eurostars grant to develop RNAi gene therapy for Huntington’s disease

May 14, 2013
uniQure raises EUR 14.1m in new investment led by Coller Capital

Feb 20, 2013
uniQure Named to MIT Technology Review’s 2013 50 Disruptive Companies List Recognizing World’s Most Innovative Companies

Jan 22, 2013
uniQure Appoints Philip Astley-Sparke President US

Dec 11, 2012
uniQure initiates Phase I in acute intermittent porphyria

Dec 6, 2012
uniQure Appoints Hans Christian Rohde Chief Commercial Officer

Dec 5, 2012
uniQure licenses RNA interference technology to advance Huntington’s disease program

Nov 5, 2012
uniQure Provides Business Update for the Third Quarter 2012

Nov 2, 2012
uniQure’s Glybera® First Gene Therapy Approved by European Commission

Sep 7, 2012
uniQure Reports Half Year Results 2012

Jul 20, 2012
First gene therapy in Western world receives positive opinion in Europe from CHMP

Jul 6, 2012
Notice to convene the Meeting of Holders of Depositary Receipts of Stichting Administratiekantoor uniQure B.V.

Jun 20, 2012
uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinson’s Disease

Jun 18, 2012
uniQure Extends Collaboration with Protein Sciences Corporation on Use of its expresSF+® Cell Line for Gene Therapy

Apr 26, 2012
Overview of key transaction elements and timetable with regard to the public-to-private and financing transaction between AMT and uniQure BV

Apr 26, 2012
Amsterdam Molecular Therapeutics completes advance distribution of uniQure depositary receipts to AMT shareholders

Apr 6, 2012
Amsterdam Molecular Therapeutics announces completion of disposal of its operations to uniQure B.V. and its dissolution becoming effective

Mar 8, 2012
uniQure Q&A

Feb 20, 2012
Invitation to informational meeting – February 23, 2012

Feb 17, 2012
Amsterdam Molecular Therapeutics Business to be Acquired by uniQure BV


Archived News Releases

2012

2011